Remus PharmaceuticalsNSE:REMUS -3.80%55 Gross Margin % is 13.40% as of Mar. 2026, which is 55% below its 10-year median of 29.95. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 116 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 55.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Remus Pharmaceuticals had a gross margin of 13.40% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Remus Pharmaceuticals Gross Margin % Related Terms
Remus Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: Gross Margin % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Remus Pharmaceuticals (NSE:REMUS) has a Gross Margin % of 13.40% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Remus Pharmaceuticals and its competitors. This is 55% below median its historical median of 29.95. Over the past decade, Remus Pharmaceuticals' Gross Margin % has ranged from 13.05 to 50.28. According to the industry distribution chart, Remus Pharmaceuticals ranks #64 out of 116 companies in the Medical Distribution industry, placing it in the top 55.2%.
Is Remus Pharmaceuticals' Gross Margin % too high?
Remus Pharmaceuticals' current Gross Margin % of 13.40% is 55% below median its 10-year median of 29.95. Over the past 10 years, this metric has ranged from a low of 13.05 to a high of 50.28. The Medical Distribution industry median Gross Margin % is 14.90. Remus Pharmaceuticals' value of 13.40% is 10.1% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #64 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #64 out of 116 companies for Gross Margin %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 14.90. Remus Pharmaceuticals' value of 13.40% is 10.1% below this benchmark. Historically, Remus Pharmaceuticals' own Gross Margin % has ranged from 13.05 to 50.28 over the past decade. While the company's 10-year median is 29.95 vs. the industry median of 14.90, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Gross Margin % of 13.40% is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Gross Margin % is 13.40%, which is 55% below median its own 10-year median of 29.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹763.55 — trading 63.1% below its estimated fair value. The current Gross Margin % is 13.40%, which is 55% below median its 10-year median of 29.95 and 10.1% below the Medical Distribution industry median of 14.90. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Gross Margin % is 13.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹763.55 is trading 63.1% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Gross Margin %: 13.40% (55% below median its 10-year median of 29.95)
GF Value™: ₹2,071.36 vs. price of ₹763.55 (63.1% below fair value)
Industry Position: 10.1% below the Medical Distribution median (#64 of 116)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
